Darell D. Bigner
Duke University
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
CAR-T cell therapy research
Solid evidence · 3 supporting papers · latest 2026
Glioma Diagnosis and Treatment
Solid evidence · 4 supporting papers · latest 2026
Immunotherapy and Immune Responses
Solid evidence · 1 supporting paper · latest 2025
Multiple Sclerosis Research Studies
Supporting evidence · 1 supporting paper · latest 2025
Immune cells in cancer
Supporting evidence · 1 supporting paper · latest 2026
CNS Lymphoma Diagnosis and Treatment
Supporting evidence · 1 supporting paper · latest 2025
Polyomavirus and related diseases
Supporting evidence · 1 supporting paper · latest 2025
Cerebrospinal fluid and hydrocephalus
Supporting evidence · 1 supporting paper · latest 2025
Publications (5)
D2C7 CAR specifically targets tumor-associated EGFR and is effective against peripheral and intracranial cancers 3321
2025DOI
TIP-27. An assessment of the Tumor Monorail Device (TMD) for repeated sampling as part of a trial evaluating the combination of D2C7-IT and an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery (CED) and cervical perilymphatic injections (CPLIs) of 2141-V11 in recurrent glioblastoma (rGBM) patients
2025DOI
Anti-VEGF vascular remodeling drives germinal center B cell-rich tertiary lymphoid structures during antibody-toxin and anti-CD40 combination therapy in glioblastoma
2026DOIPMID 42040926
CTIM-30. INVESTIGATION OF THE COMBINATION OF D2C7-IT WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) WHEN ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 COMPARED TO D2C7-IT CED MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM)
2025DOI
Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
2025DOIPMID 41270238
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Duke University
Source: OpenAlex · retrieved 2026-09-29
Source: ScienceWe Extractor · retrieved 2026-09-27